Vaxart Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Steven Lo

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	1yr
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	3.1yrs
Styrelsens genomsnittliga mandatperiod	3.6yrs

Senaste uppdateringar av ledningen

Recent updates

VD OCH KONCERNCHEF

Steven Lo (57 yo)

1yr

Anställning

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Sean Tucker	Senior VP & Chief Scientific Officer	15.1yrs	US$1.14m	0.18% MX$ 4.3m
James Cummings	Chief Medical Officer	3.6yrs	US$1.17m	0.071% MX$ 1.7m
Steven Lo	President	1yr	inga uppgifter	inga uppgifter
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2.3yrs	inga uppgifter	0.041% MX$ 965.2k
Raymond Stapleton	Chief Technology Officer	2.6yrs	inga uppgifter	inga uppgifter
Edward Berg	Senior VP & General Counsel	3.1yrs	inga uppgifter	0.056% MX$ 1.3m
Laurie Hastings	Senior Vice President of Human Resources	less than a year	inga uppgifter	inga uppgifter
Shaily Garg	Senior Vice President of Clinical Development & Project Management	5yrs	inga uppgifter	inga uppgifter
Rajesh Kapoor	Senior Vice President of Quality	4.2yrs	inga uppgifter	inga uppgifter

3.1yrs

Genomsnittlig anställningstid

56.5yo

Genomsnittlig ålder

Erfaren ledning: VXRT * s ledningsgrupp anses vara erfaren ( 3.1 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Steven Lo	President	1yr	inga uppgifter	inga uppgifter
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
Elaine Heron	Independent Director	2.6yrs	US$89.08k	0.011% MX$ 256.6k
Michael Finney	Independent Chairman of the Board	7.1yrs	US$109.57k	0.29% MX$ 7.0m
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
David Wheadon	Independent Director	3.9yrs	US$93.72k	0.0065% MX$ 153.9k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
William Watson	Independent Director	2.6yrs	US$94.76k	0.023% MX$ 546.2k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.6yrs	inga uppgifter	inga uppgifter

3.6yrs

Genomsnittlig anställningstid

69.5yo

Genomsnittlig ålder

Erfaren styrelse: VXRT * s styrelse anses vara erfaren ( 3.6 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/22 21:50
Aktiekurs vid dagens slut	2024/12/23 00:00
Intäkter	2024/12/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Vaxart, Inc. bevakas av 6 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
Jay Olson	Oppenheimer & Co. Inc.

Vaxart Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Vaxart, Inc. Announces Board and Committee Changes

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Recent updates

Vaxart Reports Topline 12-Month Safety Data from the 400-Participant Sentinel Safety Cohort of the Phase 2B Clinical Trial of Its Oral Pill Covid-19 Vaccine

Vaxart, Inc. Announces Board and Committee Changes

Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine Trial

Daniel P. Houle Issues an Investor Presentation

Daniel Houle Issues Letter to Shareholders of Vaxart

Daniel P. Houle Provides Information to Shareholders of Vaxart

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Vaxart Receives a Letter from the Office of the General Counsel of Nasdaq

Richard John Burgess Responds to Vaxart’s Governance Announcements

Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine Candidate

Richard John Burgess Files an Exempt Solicitation Statement with Vaxart

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock Split

Richard John Burgess Oppose Vaxart’s Latest Reverse Stock Split

Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI Index

Vaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08

Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.16 loss in 2Q 2023)

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Independent Director recently bought Mex$250k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.19 loss in 1Q 2023)

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors